EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta‐analysis

Riddhita De iD, Emily C C Smith, Janani Navagnanavel, Emily Au, Kateryna Maksyutynska, Maria Papoulias, Raghunath Singh, Kristoffer J Panganiban, Bailey Humber, Grimur Høgnason Mohr, Mette Ødegaard Nielsen iD, Bjørn H Ebdrup und 3 weitere

Acta Psychiatrica Scandinavica · 2025-02 · 151 (2) · 109-126

DOI: 10.1111/acps.13758 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Psychiatrica Scandinavica, online erschienen am 17.09.2024. Verfasst von Riddhita De und 14 weiteren Autor:innen. Beteiligte Einrichtung: Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonadherence/discontinuation of antipsychotic (AP) medications represents an important clinical issue in patients across psychiatric disorders, including schizophrenia spectrum disorders (SSDs). While antipsychotic‐induced weight gain (AIWG) is a reported contributor to nonadherence, a systematic review of the association between AIWG and medication nonadherence/discontinuation has not been explored previously.

Method

A systematic search was conducted in MEDLINE, EMBASE, PsychINFO, CINAHL, and CENTRAL databases, among others, to help identify all studies which explored adherence, study dropouts, AP switching and/or discontinuations attributable to AIWG among individuals with severe mental illness. A meta‐analysis was also completed where applicable.

Results

We identified two categories of studies for the meta‐analysis. Category 1 included three studies, which compared measures of AP adherence or discontinuation across BMI classes/degrees of self‐reported weight gain. When compared to normal weight individuals receiving APs or those who did not report AIWG, individuals who were either overweight or obese or reported weight gain in relation to AP use had an increased odds of AP nonadherence (OR 2.37; 95% CI 1.51–3.73; p = 0.0002). Category 2 had 14 studies which compared measures of discontinuation related to weight gain reported as an adverse effect across different APs. Olanzapine was associated with a 3.32 times (95% CI 2.32–4.74; p < 0.00001) increased likelihood of nonadherence or discontinuation when compared to other APs with lower weight gain liabilities. Similarly, APs with moderate weight gain liability (paliperidone, risperidone, and quetiapine) increased the odds of nonadherence or discontinuation by 2.25 (95% CI 1.31–3.87; p = 0.003) when compared to APs considered to have lower weight gain liability (i.e. haloperidol and aripiprazole). The qualitative summary also confirmed these findings.

Conclusion

This review and meta‐analysis suggests that AIWG influences medication nonadherence/discontinuation, whereby APs with higher weight gain liability are associated with nonadherence/discontinuation. Additional studies are needed to confirm these findings.

Schlagwörter

Stichwörter der Autor:innen

antipsychoticsdiscontinuationnonadherenceschizophreniaweight gain

Autor:innen und Institutionen

  • Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, Canada.
  • Center for Neuropsychiatric Schizophrenia Research (CNSR), Mental Health Center Glostrup, University of Copenhagen, Glostrup, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Unit for Complicated Schizophrenia, Mental Health Center Glostrup, University of Copenhagen, Glostrup, Denmark.
  • Department of Psychiatry, University of Toronto, Toronto, Canada.

ORCID-Profile: Riddhita De, Mette Ødegaard Nielsen, Margaret K Hahn

Zitieren

APA

De, R., Smith, E. C. C., Navagnanavel, J., Au, E., Maksyutynska, K., Papoulias, M., Singh, R., Panganiban, K. J., Humber, B., Mohr, G. H., Nielsen, M. Ø., Ebdrup, B. H., Remington, G., Agarwal, S. M., & Hahn, M. K. (2025). The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica, 151(2), 109-126. https://doi.org/10.1111/acps.13758

Vancouver

De R, Smith ECC, Navagnanavel J, Au E, Maksyutynska K, Papoulias M, et al. The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica. 2025;151(2):109-126. doi:10.1111/acps.13758

BibTeX
@article{De2025,
  author = {De, Riddhita and Smith, Emily C C and Navagnanavel, Janani and Au, Emily and Maksyutynska, Kateryna and Papoulias, Maria and Singh, Raghunath and Panganiban, Kristoffer J and Humber, Bailey and Mohr, Grimur Høgnason and Nielsen, Mette Ødegaard and Ebdrup, Bjørn H and Remington, Gary and Agarwal, Sri Mahavir and Hahn, Margaret K},
  title = {The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta‐analysis},
  journal = {Acta Psychiatrica Scandinavica},
  year = {2025},
  volume = {151},
  number = {2},
  pages = {109--126},
  doi = {10.1111/acps.13758}
}
Kostenlos starten →